Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan
Mitsuhiro Itagaki, Hiroshi Kuwazawa, Shun Sasaki, Moe Matsuura, Yudai Tanaka, Naoshi Obara · 2026
Read Long-term safety and effectiveness of romiplostim in patients with refractory aplastic anemia: a nationwide, all-case, post-marketing surveillance study in Japan by Mitsuhiro Itagaki, Hiroshi Kuwazawa, Shun Sasaki, Moe Matsuura, Yudai Tanaka, Naoshi Obara (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421184.txt.
Description
Mitsuhiro Itagaki and colleagues tracked romiplostim safety and benefit in 2026 for refractory aplastic anemia across Japan, registering every patient who started the drug from 2019 to 2021. The bone-marrow failure disease leaves patients short of all blood cells, and the weekly thrombopoietin drug's long-term record needed a full national check.
Among 470 patients, adverse events hit 57 percent and drug reactions 18 percent, with clots, blood tumors, and bleeding each under 2 percent. Blood responses reached about 79 percent at 27 weeks and 84 percent at 52 weeks. The paper supports long-term romiplostim as effective and manageable with watchfulness for rare serious events.
Catalog record
| CREATOR | Mitsuhiro Itagaki, Hiroshi Kuwazawa, Shun Sasaki, Moe Matsuura, Yudai Tanaka, Naoshi Obara |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |